FDA Approves New Interchangeable Biosimilar to Pertuzumab By Ogkologos - December 3, 2025 62 0 Facebook Twitter Google+ Pinterest WhatsApp Approval is based on comparisons across a broad range of structural and functional product quality attributes Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR Promising Results Are Provided by Tebentafusp in Metastatic Uveal Melanoma December 12, 2020 EMA Recommends Granting a Marketing Authorisation for Sugemalimab June 21, 2024 Coronavirus y COVID-19: Qué deben saber las personas con cáncer June 24, 2020 A Blood-Based, Multigenomic Signature is an Effective Diagnostic and Has Clinical... August 16, 2021 Load more HOT NEWS Diagnosed With Breast Cancer At 24, Her Biggest Fear Wasn’t Death... ΝΕΑ ΓΙΑ ΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ Immunotherapy Combination That Targets TIGIT Receptor Shows Promise in Non-Small Cell... FDA Approves First Adenoviral Vector-Based Gene Therapy for High-Risk Bacillus Calmette-Guérin...